Duloxetine Capsule, Delayed Release
Product Images NDC 68788-8782

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-8782). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (69d6387b 794f 415d 8013 23cca0a6984f 01)

Chemical structure of Duloxetine as shown in the image, depicting its molecular arrangement including aromatic rings, oxygen, sulfur atoms, and the hydrochloride (HCl) component.*

FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 02)

Kaplan-Meier estimator method graph depicting the proportion of patients with relapse over time in days from randomization. The graph compares relapse rates between patients treated with Duloxetine and those given placebo, showing lower relapse proportion for Duloxetine over a 200-day period.*

FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 03)

Kaplan-Meier survival curve displaying the proportion of patients experiencing relapse over time in days, comparing Duloxetine treatment with placebo. The x-axis represents time from randomization to relapse and the y-axis shows the proportion of patients with relapse. Duloxetine treatment curve shows a lower relapse proportion than placebo over the study duration.*

FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The chart compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, illustrating patient improvement rates across different pain improvement percentages.*

FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 05)

A line graph depicting percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, showing higher improvement percentages in the Duloxetine groups across varying levels of pain improvement.*

FDA Label Image

Fig 5 (69d6387b 794f 415d 8013 23cca0a6984f 06)

A line graph showing the percentage of patients improved relative to percent improvement in pain from baseline for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved. Three lines compare the outcomes for the two Duloxetine dosing schedules against placebo.*

FDA Label Image

Fig 6 (69d6387b 794f 415d 8013 23cca0a6984f 07)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. Four lines represent treatment groups: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 60 mg once daily (alternative label), and placebo. The graph compares patient improvement across various pain improvement thresholds.*

FDA Label Image

Fig 7 (69d6387b 794f 415d 8013 23cca0a6984f 08)

A line graph showing the percentage of pediatric patients aged 13 to 17 years with juvenile fibromyalgia syndrome achieving various levels of pain relief at week 12. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Two lines compare duloxetine 60 mg once daily and placebo, illustrating higher pain relief percentages for duloxetine across improvement levels.*

FDA Label Image

Figure 8 (69d6387b 794f 415d 8013 23cca0a6984f 09)

A line graph comparing the percentage of patients improved at different levels of percent improvement in pain from baseline for Duloxetine 60/120 mg once daily versus placebo. The x-axis shows percent improvement in pain, and the y-axis shows the percentage of patients improved. Duloxetine consistently shows higher patient improvement percentages than placebo across pain improvement levels.*

FDA Label Image

Figure 9 (69d6387b 794f 415d 8013 23cca0a6984f 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines represent placebo and Duloxetine 60 mg once daily, illustrating the distribution of patient improvement levels.*

FDA Label Image

Figure 10 (69d6387b 794f 415d 8013 23cca0a6984f 11)

A clinical response chart comparing percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo groups. The graph shows two data lines plotted over a pain improvement scale from >0 to 100%, with Duloxetine consistently showing higher patient improvement percentages than placebo.*

FDA Label Image

Duloxetine Delayed-release Cap Usp 40mg (69d6387b 794f 415d 8013 23cca0a6984f 15)

Label for Duloxetine Delayed-Release Capsules USP 40 mg, generic for Cymbalta, manufactured by Lupin Limited. Label features dosage and storage instructions, with warnings and batch information fields. The label has bilingual dosing directions in English and Spanish on a bright yellow background, and includes barcodes and the Preferred Pharmaceuticals Inc. logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.